Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
GLPG1837 dose 2
DRUG
2 trials
Sponsors
Galapagos NV
Conditions
Cystic Fibrosis
Phase 2
Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)
Completed
NCT02690519
Galapagos NV
Cystic Fibrosis
Start: 2016-01-31
End: 2016-09-30
Updated: 2016-10-11
Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)
Completed
NCT02707562
Galapagos NV
Cystic Fibrosis
Start: 2016-02-29
End: 2016-11-30
Updated: 2016-12-07
Related Papers
GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).
2019-05-27
19 citations